Advisory Opinion Proceeding; Certain Sleep-Disordered Breathing Treatment Systems and Components Thereof; Institution of an Advisory Opinion Proceeding, 76320-76321 [2013-29887]
Download as PDF
<![CDATA[
76320
Federal Register / Vol. 78, No. 242 / Tuesday, December 17, 2013 / Notices
Management California State Office,
Sacramento, California, thirty (30)
calendar days from the date of this
publication.
A copy of the plats may be
obtained from the California State
Office, Bureau of Land Management,
2800 Cottage Way, Sacramento,
California 95825, upon required
payment.
Protest: A person or party who wishes
to protest a survey must file a notice
that they wish to protest with the
California State Director, Bureau of
Land Management, 2800 Cottage Way,
Sacramento, California, 95825.
FOR FURTHER INFORMATION CONTACT:
Chief, Branch of Geographic Services,
Bureau of Land Management, California
State Office, 2800 Cottage Way, Room
W–1623, Sacramento, California 95825,
(916) 978–4310.
SUPPLEMENTARY INFORMATION: These
surveys were executed to meet the
administrative needs of various federal
agencies; the Bureau of Land
Management, Bureau of Indian Affairs
or Bureau of Reclamation. The lands
surveyed are:
ADDRESSES:
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Mount Diablo Meridian, California
T. 31 S., R. 16 E., dependent resurvey and
metes-and-bounds survey accepted July
19, 2013.
T. 23 S., R. 16 E., dependent resurvey and
subdivision of section 28 accepted
August 8, 2013.
T. 6 N., R. 17 E., amended protraction
diagram for unsurveyed area accepted
August 9, 2013.
T. 18 N., R. 11 W., dependent resurvey and
subdivision accepted August 19, 2013.
T. 21 N., R. 15 E., dependent resurvey and
subdivision of sections accepted
November 4, 2013.
T. 45 N., R. 15 E., dependent resurvey and
subdivision accepted November 4, 2013.
T. 26 S., R. 36 E., dependent resurvey
accepted November 8, 2013.
T. 18 N., R. 1 W., metes-and-bounds survey
accepted December 4, 2013.
San Bernardino Meridian, California
T. 1 S., R. 17 W., dependent resurvey, metesand-bounds survey and informative
traverse accepted July 12, 2013.
T. 7 S., R. 12 E., dependent resurvey,
subdivision of sections and metes-andbounds survey accepted August 8, 2013.
T. 8 S., R. 12 E., dependent resurvey,
subdivision of sections and metes-andbounds survey accepted August 19,
2013.
T. 9 S., R. 14 E., dependent resurvey and
metes-and-bounds survey accepted
August 19, 2013.
T. 9 S., R. 13 E., dependent resurvey,
subdivision of sections and metes-andbounds survey accepted August 20,
2013.
T. 10 S., R. 14 E., dependent resurvey,
subdivision of sections and metes-and-
VerDate Mar<15>2010
14:45 Dec 16, 2013
Jkt 232001
bounds survey accepted September 18,
2013.
T. 7 S., R. 13 E., dependent resurvey,
subdivision of sections and metes-andbounds survey accepted September 18,
2013.
T. 11 S., R. 15 E., dependent resurvey
accepted September 19, 2013.
T. 11 S., R. 16 E., dependent resurvey
accepted September 19, 2013.
T. 10 S., R. 18 E., dependent resurvey
accepted September 19, 2013.
T. 9 S., R. 16 E., dependent resurvey,
subdivision of sections and metes-andbounds survey accepted September 19,
2013.
T. 10 S., R. 15 E., dependent resurvey and
metes-and-bounds survey accepted
September 19, 2013.
T. 12 S., R. 16 E., dependent resurvey and
informative traverse accepted September
19, 2013.
T. 11 S., R. 19 E., dependent resurvey and
retracement accepted September 20,
2013.
T. 13 S., R. 18 E., dependent resurvey,
independent resurvey and subdivision of
section accepted September 24, 2013.
T. 12 S., R. 17 E., dependent resurvey and
informative traverse accepted September
24, 2013.
T. 9 S., R. 17 E., dependent resurvey,
independent resurvey, subdivision of
sections, informative traverse and metesand-bounds survey accepted September
25, 2013.
T. 10 S., R. 19 E., dependent resurvey and
independent resurvey accepted
September 25, 2013.
T. 12 S., R. 19 E., dependent resurvey and
subdivision of section accepted
September 25, 2013.
T. 3 S., R. 1 E., supplemental plat of tract 52
in section 1 accepted November 14,
2013.
T. 2 N., R. 5 W., dependent resurvey and
subdivision of fractional sections 26, 27,
35, and 36 accepted November 21, 2013.
T. 7 S., R. 12 E., supplemental plat of the S
1/2 of section 34 accepted November 26,
2013.
T. 7 S., R. 12 E., supplemental plat of the S
1/2 of section 35 accepted November 26,
2013.
T. 7 S., R. 12 E., supplemental plat of the SW
1/4 of section 36 accepted November 26,
2013.
T. 7 S., R. 13 E., supplemental plat of section
31 accepted November 27, 2013.
T. 7 S., R. 13 E., supplemental plat of
sections 13 and 14 accepted November
27, 2013.
T. 7 S., R. 13 E., supplemental plat of the NW
1/4 of section 22 accepted November 27,
2013.
T. 8 S., R. 12 E., supplemental plat of section
2 accepted November 27, 2013.
T. 10 S., R. 14 E., supplemental plat of the
E 1/2 of the NE 1/4 of section 22
accepted November 27, 2013.
Humboldt Meridian, California
T. 12 N., R. 2 E., dependent resurvey,
subdivision and survey accepted August
8, 2013.
Authority: 43 U.S.C., Chapter 3.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Dated: December 9, 2013.
Lance J. Bishop,
Chief Cadastral Surveyor, California.
[FR Doc. 2013–29943 Filed 12–16–13; 8:45 am]
BILLING CODE 4310–40–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–879]
Advisory Opinion Proceeding; Certain
Sleep-Disordered Breathing Treatment
Systems and Components Thereof;
Institution of an Advisory Opinion
Proceeding
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined to institute
an advisory opinion proceeding in the
above-captioned investigation.
FOR FURTHER INFORMATION CONTACT:
Amanda Pitcher Fisherow, Esq., Office
of the General Counsel, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,
telephone (202) 205–2737. Copies of
non-confidential documents filed in
connection with this investigation are or
will be available for inspection during
official business hours (8:45 a.m. to 5:15
p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted the underlying
investigation on April 25, 2013, based
on a complaint filed on March 28, 2013,
and supplemented on April 19, 2013, on
behalf of ResMed Corp. of San Diego,
California; ResMed Inc. of San Diego,
California; and ResMed Ltd. of Australia
(collectively, ‘‘ResMed’’). 78 FR 25475
(May 1, 2013). The complaint alleged
violations of Section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, in the sale for importation,
importation, or sale within the United
States after importation of certain sleepdisordered breathing treatment systems
and components thereof by reason of
SUMMARY:
E:\FR\FM\17DEN1.SGM
17DEN1
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 242 / Tuesday, December 17, 2013 / Notices
infringement of claims 1, 2, 4, 5, 17, and
28 of U.S. Patent No. 6,216,691, claims
1 and 20 of U.S. Patent No. 6,935,337,
claim 15 of U.S. Patent No. 7,159,587,
claims 1, 5, 6, 11, 12, 18–20, 35, and 36
of U.S. Patent No. 7,487,772, claims 1–
7 of U.S. Patent No. 7,614,398, claims
59, 60, 63, and 72–75 of U.S. Patent No.
7,743,767, and claims 17, 21–24, 29, and
32–37 of U.S. Patent No. 7,997,267. The
Commission’s notice of investigation
named as respondents Apex Medical
Corp. of New Taipei City, Taiwan and
Apex Medical USA Corp. of Brea,
California (collectively, ‘‘Apex’’) and
Medical Depot Inc., d/b/a Drive Medical
Design & Manufacturing of Port
Washington, New York. The Office of
Unfair Import Investigations
participated in the investigation.
Medical Depot Inc. and Apex were
previously terminated from the
investigation on the basis of consent
orders. Order Nos. 8 (unreviewed by the
Commission, July 18, 2013) and 11
(unreviewed by the Commission, Aug.
8, 2013).
On September 23, 2013, Apex filed a
request with the Commission asking for
institution of an advisory opinion
proceeding to declare that their
redesigned sleep-disordered breathing
treatment systems are not covered by
the consent order. Apex also requests
that the proceeding be conducted
expeditiously. ResMed filed a response
on October 18, 2013 opposing Apex’s
request.
The Commission has determined that
Apex’s request complies with the
requirements for institution of an
advisory opinion proceeding under
Commission rule 210.79. Accordingly,
the Commission has determined to
institute an advisory opinion
proceeding and referred Apex’s request
to the Chief Administrative Law Judge
to designate a presiding administrative
law judge. The following entities are
named as parties to the proceeding: (1)
Complainant ResMed; (2) respondent
Apex; (3) the Office of Unfair Import
Investigations.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: December 11, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–29887 Filed 12–16–13; 8:45 am]
BILLING CODE 7020–02–P
VerDate Mar<15>2010
14:45 Dec 16, 2013
Jkt 232001
INTERNATIONAL TRADE
COMMISSION
[Investigation Nos. 701–TA–503–504 and
731–TA–1229–1230 (Preliminary)]
Monosodium Glutamate From China
and Indonesia
Determinations
On the basis of the record 1 developed
in the subject investigations, the United
States International Trade Commission
(Commission) determines, pursuant to
sections 703(a) and 733(a) of the Tariff
Act of 1930 (19 U.S.C. 1671b(a) and
1673b(a)) (the Act), that there is a
reasonable indication that an industry
in the United States is materially
injured by reason of imports from China
and Indonesia of monosodium
glutamate, provided for in subheading
2922.42.10 of the Harmonized Tariff
Schedule of the United States, that are
alleged to be sold in the United States
at less than fair value (LTFV) and
subsidized by the Governments of China
and Indonesia.
Commencement of Final Phase
Investigations
Pursuant to section 207.18 of the
Commission’s rules, the Commission
also gives notice of the commencement
of the final phase of its investigations.
The Commission will issue a final phase
notice of scheduling, which will be
published in the Federal Register as
provided in section 207.21 of the
Commission’s rules, upon notice from
the Department of Commerce
(Commerce) of affirmative preliminary
determinations in the investigations
under sections 703(b) or 733(b) of the
Act, or, if the preliminary
determinations are negative, upon
notice of affirmative final
determinations in those investigations
under sections 705(a) or 735(a) of the
Act. Parties that filed entries of
appearance in the preliminary phase of
the investigations need not enter a
separate appearance for the final phase
of the investigations. Industrial users,
and, if the merchandise under
investigation is sold at the retail level,
representative consumer organizations
have the right to appear as parties in
Commission antidumping and
countervailing duty investigations. The
Secretary will prepare a public service
list containing the names and addresses
of all persons, or their representatives,
who are parties to the investigations.
1 The record is defined in sec. 207.2(f) of the
Commission’s Rules of Practice and Procedure (19
CFR § 207.2(f)).
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
76321
Background
On September 16, 2013, a petition
was filed with the Commission and
Commerce by Ajinomoto North America
Inc. (‘‘AJINA’’), Itasca, Illinois, alleging
that an industry in the United States is
materially injured or threatened with
material injury by reason of LTFV
imports of monosodium glutamate from
China and Indonesia that are subsidized
by the Governments of China and
Indonesia. Accordingly, effective
September 16, 2013, the Commission
instituted countervailing duty
investigation Nos. 701–TA–503–504 and
antidumping duty investigation Nos.
731–TA–1229–1230 (Preliminary).
Notice of the institution of the
Commission’s investigations and of a
public conference to be held in
connection therewith was given by
posting copies of the notice in the Office
of the Secretary, U.S. International
Trade Commission, Washington, DC,
and by publishing the notice in the
Federal Register of September 20, 2013
(78 FR 57881). The conference was held
in Washington, DC, on October 23,
2013, and all persons who requested the
opportunity were permitted to appear in
person or by counsel.
The Commission transmitted its
determinations in these investigations to
the Secretary of Commerce on
November 18, 2013. The views of the
Commission are contained in USITC
Publication 4437 (November 2013),
entitled Monosodium Glutamate from
China and Indonesia: Investigation Nos.
701–TA–503–504 and 731–TA–1229–
1230 (Preliminary).
By order of the Commission.
Issued: November 19, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–29882 Filed 12–16–13; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–13–038]
Government in the Sunshine Act
Meeting Notice
United
States International Trade Commission.
TIME AND DATE: December 17, 2013 at
11:00 a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: None
2. Minutes
AGENCY HOLDING THE MEETING:
E:\FR\FM\17DEN1.SGM
17DEN1
]]>Agencies
[Federal Register Volume 78, Number 242 (Tuesday, December 17, 2013)]
[Notices]
[Pages 76320-76321]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-29887]
=======================================================================
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-879]
Advisory Opinion Proceeding; Certain Sleep-Disordered Breathing
Treatment Systems and Components Thereof; Institution of an Advisory
Opinion Proceeding
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the U.S. International Trade
Commission has determined to institute an advisory opinion proceeding
in the above-captioned investigation.
FOR FURTHER INFORMATION CONTACT: Amanda Pitcher Fisherow, Esq., Office
of the General Counsel, U.S. International Trade Commission, 500 E
Street SW., Washington, DC 20436, telephone (202) 205-2737. Copies of
non-confidential documents filed in connection with this investigation
are or will be available for inspection during official business hours
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW., Washington, DC 20436,
telephone (202) 205-2000. General information concerning the Commission
may also be obtained by accessing its Internet server at https://www.usitc.gov. The public record for this investigation may be viewed
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov.
Hearing-impaired persons are advised that information on this matter
can be obtained by contacting the Commission's TDD terminal on (202)
205-1810.
SUPPLEMENTARY INFORMATION: The Commission instituted the underlying
investigation on April 25, 2013, based on a complaint filed on March
28, 2013, and supplemented on April 19, 2013, on behalf of ResMed Corp.
of San Diego, California; ResMed Inc. of San Diego, California; and
ResMed Ltd. of Australia (collectively, ``ResMed''). 78 FR 25475 (May
1, 2013). The complaint alleged violations of Section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C. 1337, in the sale for importation,
importation, or sale within the United States after importation of
certain sleep-disordered breathing treatment systems and components
thereof by reason of
[[Page 76321]]
infringement of claims 1, 2, 4, 5, 17, and 28 of U.S. Patent No.
6,216,691, claims 1 and 20 of U.S. Patent No. 6,935,337, claim 15 of
U.S. Patent No. 7,159,587, claims 1, 5, 6, 11, 12, 18-20, 35, and 36 of
U.S. Patent No. 7,487,772, claims 1-7 of U.S. Patent No. 7,614,398,
claims 59, 60, 63, and 72-75 of U.S. Patent No. 7,743,767, and claims
17, 21-24, 29, and 32-37 of U.S. Patent No. 7,997,267. The Commission's
notice of investigation named as respondents Apex Medical Corp. of New
Taipei City, Taiwan and Apex Medical USA Corp. of Brea, California
(collectively, ``Apex'') and Medical Depot Inc., d/b/a Drive Medical
Design & Manufacturing of Port Washington, New York. The Office of
Unfair Import Investigations participated in the investigation.
Medical Depot Inc. and Apex were previously terminated from the
investigation on the basis of consent orders. Order Nos. 8 (unreviewed
by the Commission, July 18, 2013) and 11 (unreviewed by the Commission,
Aug. 8, 2013).
On September 23, 2013, Apex filed a request with the Commission
asking for institution of an advisory opinion proceeding to declare
that their redesigned sleep-disordered breathing treatment systems are
not covered by the consent order. Apex also requests that the
proceeding be conducted expeditiously. ResMed filed a response on
October 18, 2013 opposing Apex's request.
The Commission has determined that Apex's request complies with the
requirements for institution of an advisory opinion proceeding under
Commission rule 210.79. Accordingly, the Commission has determined to
institute an advisory opinion proceeding and referred Apex's request to
the Chief Administrative Law Judge to designate a presiding
administrative law judge. The following entities are named as parties
to the proceeding: (1) Complainant ResMed; (2) respondent Apex; (3) the
Office of Unfair Import Investigations.
The authority for the Commission's determination is contained in
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: December 11, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013-29887 Filed 12-16-13; 8:45 am]
BILLING CODE 7020-02-P
